KALYDECO GRANULES

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

IVACAFTOR

Sẵn có từ:

VERTEX PHARMACEUTICALS (CANADA) INCORPORATED

Mã ATC:

R07AX02

INN (Tên quốc tế):

IVACAFTOR

Liều dùng:

75MG

Dạng dược phẩm:

GRANULES

Thành phần:

IVACAFTOR 75MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

56 PACKETS

Loại thuốc theo toa:

Prescription

Khu trị liệu:

Cystic Fibrosis Transmembrane Conductance Regulator Potentiators

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0153450003; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2015-06-12

Đặc tính sản phẩm

_ _
_Pr_
_KALYDECO_
_®_
_ (ivacaftor) Tablets and Granules _
_Page 1 of 43_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
KALYDECO
®
Ivacaftor Tablets
Tablets: 150 mg, Oral
Ivacaftor Granules
Granules: 13.4 mg per packet, 25 mg per packet, 50 mg per packet, and
75 mg per packet,
Oral
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator
ATC R07AX02
Vertex Pharmaceuticals (Canada) Incorporated
20 Bay Street, Suite 1520
Toronto, Ontario
M5J 2N8
Date of Initial Authorization:
Nov 26, 2012
Date of Revision:
Nov 27, 2023
Submission Control Number: 273575
_ _
_KALYDECO (ivacaftor) Tablets and Granules _
_Page 2 of 43_
RECENT MAJOR LABEL CHANGES
1 Indications
11/2023
1 Indications, 1.1 Pediatrics
11/2023
4 Dosage and Administration
11/2023
7 Warnings and Precautions
11/2023
7 Warnings and Precautions, 7.1.3 Pediatrics
11/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................
2
TABLE OF CONTENTS
.................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................... 4
1
INDICATIONS
.....................................................................................................
4
1.1
Pediatrics
....................................................................................................
4
1.2
Geriatrics
....................................................................................................
4
2
CONTRAINDICATIONS
......................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................... 4
4.1
Dosing
Considerations................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
.........................................